An overview of immune checkpoint inhibitors in breast cancer

Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors wi...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Federica Miglietta [verfasserIn] Maria Silvia Cona [verfasserIn] Maria Vittoria Dieci [verfasserIn] Valentina Guarneri [verfasserIn] Nicla La Verde [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors

Übergeordnetes Werk:	In: Exploration of Targeted Anti-tumor Therapy - Open Exploration Publishing Inc., 2021, 1(2020), 6, Seite 452-472
Übergeordnetes Werk:	volume:1 ; year:2020 ; number:6 ; pages:452-472

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.37349/etat.2020.00029

Katalog-ID:	DOAJ061689416

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ061689416
003	DE-627
005	20230309013237.0
007	cr uuu---uuuuu
008	230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.37349/etat.2020.00029 \|2 doi
035			\|a (DE-627)DOAJ061689416
035			\|a (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC31-1245
100	0		\|a Federica Miglietta \|e verfasserin \|4 aut
245	1	3	\|a An overview of immune checkpoint inhibitors in breast cancer
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.
650		4	\|a early breast cancer
650		4	\|a metastatic breast cancer
650		4	\|a immunotherapy
650		4	\|a immune checkpoint inhibitors
653		0	\|a Internal medicine
700	0		\|a Maria Silvia Cona \|e verfasserin \|4 aut
700	0		\|a Maria Vittoria Dieci \|e verfasserin \|4 aut
700	0		\|a Valentina Guarneri \|e verfasserin \|4 aut
700	0		\|a Nicla La Verde \|e verfasserin \|4 aut
773	0	8	\|i In \|t Exploration of Targeted Anti-tumor Therapy \|d Open Exploration Publishing Inc., 2021 \|g 1(2020), 6, Seite 452-472 \|w (DE-627)174398264X \|x 26923114 \|7 nnns
773	1	8	\|g volume:1 \|g year:2020 \|g number:6 \|g pages:452-472
856	4	0	\|u https://doi.org/10.37349/etat.2020.00029 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 \|z kostenfrei
856	4	0	\|u https://www.explorationpub.com/Journals/etat/Article/100229 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2692-3114 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 1 \|j 2020 \|e 6 \|h 452-472

Indexfelder

author_variant	f m fm m s c msc m v d mvd v g vg n l v nlv
matchkey_str	article:26923114:2020----::nvriwfmuehcpitniios
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472
spelling	10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472
allfields_unstemmed	10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472
allfieldsGer	10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472
allfieldsSound	10.37349/etat.2020.00029 doi (DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25 DE-627 ger DE-627 rakwb eng RC31-1245 Federica Miglietta verfasserin aut An overview of immune checkpoint inhibitors in breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting. early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine Maria Silvia Cona verfasserin aut Maria Vittoria Dieci verfasserin aut Valentina Guarneri verfasserin aut Nicla La Verde verfasserin aut In Exploration of Targeted Anti-tumor Therapy Open Exploration Publishing Inc., 2021 1(2020), 6, Seite 452-472 (DE-627)174398264X 26923114 nnns volume:1 year:2020 number:6 pages:452-472 https://doi.org/10.37349/etat.2020.00029 kostenfrei https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 kostenfrei https://www.explorationpub.com/Journals/etat/Article/100229 kostenfrei https://doaj.org/toc/2692-3114 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2020 6 452-472
language	English
source	In Exploration of Targeted Anti-tumor Therapy 1(2020), 6, Seite 452-472 volume:1 year:2020 number:6 pages:452-472
sourceStr	In Exploration of Targeted Anti-tumor Therapy 1(2020), 6, Seite 452-472 volume:1 year:2020 number:6 pages:452-472
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors Internal medicine
isfreeaccess_bool	true
container_title	Exploration of Targeted Anti-tumor Therapy
authorswithroles_txt_mv	Federica Miglietta @@aut@@ Maria Silvia Cona @@aut@@ Maria Vittoria Dieci @@aut@@ Valentina Guarneri @@aut@@ Nicla La Verde @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	174398264X
id	DOAJ061689416
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689416</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013237.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Federica Miglietta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="3"><subfield code="a">An overview of immune checkpoint inhibitors in breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">early breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastatic breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Silvia Cona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Vittoria Dieci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 6, Seite 452-472</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:452-472</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100229</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="h">452-472</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Federica Miglietta
spellingShingle	Federica Miglietta misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine An overview of immune checkpoint inhibitors in breast cancer
authorStr	Federica Miglietta
ppnlink_with_tag_str_mv	@@773@@(DE-627)174398264X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC31-1245
illustrated	Not Illustrated
issn	26923114
topic_title	RC31-1245 An overview of immune checkpoint inhibitors in breast cancer early breast cancer metastatic breast cancer immunotherapy immune checkpoint inhibitors
topic	misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine
topic_unstemmed	misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine
topic_browse	misc RC31-1245 misc early breast cancer misc metastatic breast cancer misc immunotherapy misc immune checkpoint inhibitors misc Internal medicine
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Exploration of Targeted Anti-tumor Therapy
hierarchy_parent_id	174398264X
hierarchy_top_title	Exploration of Targeted Anti-tumor Therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)174398264X
title	An overview of immune checkpoint inhibitors in breast cancer
ctrlnum	(DE-627)DOAJ061689416 (DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25
title_full	An overview of immune checkpoint inhibitors in breast cancer
author_sort	Federica Miglietta
journal	Exploration of Targeted Anti-tumor Therapy
journalStr	Exploration of Targeted Anti-tumor Therapy
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	452
author_browse	Federica Miglietta Maria Silvia Cona Maria Vittoria Dieci Valentina Guarneri Nicla La Verde
container_volume	1
class	RC31-1245
format_se	Elektronische Aufsätze
author-letter	Federica Miglietta
doi_str_mv	10.37349/etat.2020.00029
author2-role	verfasserin
title_sort	overview of immune checkpoint inhibitors in breast cancer
callnumber	RC31-1245
title_auth	An overview of immune checkpoint inhibitors in breast cancer
abstract	Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.
abstractGer	Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.
abstract_unstemmed	Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6
title_short	An overview of immune checkpoint inhibitors in breast cancer
url	https://doi.org/10.37349/etat.2020.00029 https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25 https://www.explorationpub.com/Journals/etat/Article/100229 https://doaj.org/toc/2692-3114
remote_bool	true
author2	Maria Silvia Cona Maria Vittoria Dieci Valentina Guarneri Nicla La Verde
author2Str	Maria Silvia Cona Maria Vittoria Dieci Valentina Guarneri Nicla La Verde
ppnlink	174398264X
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.37349/etat.2020.00029
callnumber-a	RC31-1245
up_date	2024-07-03T22:10:43.839Z
_version_	1803597532460220416
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061689416</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309013237.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37349/etat.2020.00029</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061689416</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4ee0504bb2dd49738a1b472c282bcb25</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Federica Miglietta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="3"><subfield code="a">An overview of immune checkpoint inhibitors in breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Although breast cancer is not traditionally considered an immunogenic type of tumor, the combination of immunotherapy and chemotherapy has recently emerged as a novel treatment option in triple-negative subtype in the advanced setting and other similar combinations of immune checkpoint inhibitors with chemotherapy are expected to become part of the neoadjuvant management in the near future. In addition, encouraging results have been observed with the combination of immune checkpoint blockade with diverse biological agents, including anti-HER2 agents, CDK 4/6 inhibitors, PARP-inhibitors. The present review summarized the available evidence coming from clinical trials on the role of immune checkpoint inhibitors in the management of breast cancer, both in advanced and early setting.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">early breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">metastatic breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Silvia Cona</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Vittoria Dieci</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Exploration of Targeted Anti-tumor Therapy</subfield><subfield code="d">Open Exploration Publishing Inc., 2021</subfield><subfield code="g">1(2020), 6, Seite 452-472</subfield><subfield code="w">(DE-627)174398264X</subfield><subfield code="x">26923114</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:452-472</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37349/etat.2020.00029</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4ee0504bb2dd49738a1b472c282bcb25</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.explorationpub.com/Journals/etat/Article/100229</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2692-3114</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield><subfield code="h">452-472</subfield></datafield></record></collection>
score	7.3998213

Nicht das Richtige dabei?

Schreiben Sie uns!

An overview of immune checkpoint inhibitors in breast cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?